Currently, some STAT3 inhibitors, including small molecular compounds, peptides, and oligonucleotides, have been developed to combat PCa, and it is rational to anticipate their potential therapeutic value in clinic [23–25]. This evidence concerns the gene STAT3 and posterior cortical atrophy.